Related Experiment Video
Updated: Aug 18, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets
Mahmoud M Iravani1, Emilie Syed, Michael J Jackson
1Neurodegenerative Disease Research Centre, GKT School of Biomedical Sciences, King's College, London SE1 1UL, UK.
Abstract:
Standard MPTP treatment regimens in primates result in > 85% destruction of nigral dopaminergic neurons and the onset of marked motor deficits that respond to known symptomatic treatments for Parkinson's disease (PD). The extent of nigral degeneration reflects the late stages of PD rather than events occurring at its onset. We report on a modified MPTP treatment regimen that causes nigral dopaminergic degeneration in common marmosets equivalent to that occurring at the time of initiation of motor symptoms in man. Subcutaneous administration of MPTP 1 mg/kg for 3 consecutive days caused a reproducible 60% loss of nigral tyrosine hydroxylase (TH)-positive cells, which occurred mainly in the calbindin-D(28k)-poor nigrosomes with a similar loss of TH-immunoreactivity (TH-ir) in the caudate nucleus and the putamen. The animals showed obvious motor abnormalities with reduced bursts of activity and the onset of motor disability. However, the loss of striatal terminals did not reflect early PD because a greater loss of TH-ir occurred in the caudate nucleus than in the putamen and a marked reduction in TH-ir occurred in striatal patches compared to the matrix. Examination of striatal fibres following a partial MPTP lesion showed a conspicuous increase in the number and the diameter of large branching fibres in the putaminal and to some extent caudatal matrix, pointing to a possible compensatory sprouting of dopaminergic terminals. In addition, these partially lesioned animals did not respond to acute treatment with L-DOPA. This primate partial lesions model may be useful for examining potential neuroprotective or neurorestorative agents for PD.
Insights
A new MPTP treatment in marmosets creates early Parkinson's disease (PD) motor symptoms and a 60% loss of dopaminergic neurons. This model may help test new neuroprotective drugs for PD.
Area of Science:
- Neuroscience
- Primate models
- Parkinson's disease research
Background:
- Standard MPTP models cause severe nigral degeneration, mimicking late-stage Parkinson's disease (PD).
- A need exists for primate models reflecting early PD onset and motor symptoms.
Purpose of the Study:
- To develop a modified MPTP regimen in marmosets that mimics early-stage PD.
- To investigate the resulting dopaminergic degeneration and motor deficits.
- To evaluate the model's utility for testing therapeutic agents.
Main Methods:
- Subcutaneous administration of MPTP (1 mg/kg) for 3 consecutive days in common marmosets.
- Quantification of nigral tyrosine hydroxylase (TH)-positive cells and TH-immunoreactivity (TH-ir) in striatal regions (caudate nucleus and putamen).
- Assessment of motor abnormalities and response to L-DOPA treatment.
Main Results:
- A reproducible 60% loss of nigral TH-positive cells and reduced TH-ir in the caudate nucleus and putamen.
- Onset of motor abnormalities, including reduced activity and motor disability.
- Differential loss of TH-ir in caudate vs. putamen and striatal patches vs. matrix, not typical of early PD.
- Evidence of compensatory dopaminergic sprouting in partially lesioned animals.
- Lack of response to acute L-DOPA treatment in partially lesioned marmosets.
Conclusions:
- The modified MPTP regimen creates a primate model of early Parkinson's disease with specific dopaminergic deficits and motor symptoms.
- This model, characterized by partial nigral degeneration and compensatory sprouting, may be valuable for evaluating neuroprotective and neurorestorative therapies for PD.
- The lack of L-DOPA response in this model highlights its potential for testing agents beyond symptomatic relief.
